|Day Low/High||138.56 / 139.50|
|52 Wk Low/High||118.62 / 148.99|
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
These are simply programs where some ETFs and handcrafted baskets are overwhelming both sides of the market.
This is what the market looks like when the Fed says nothing and the president isn't ranting about something.
This is a battleground stock that has made big moves in both directions on earnings in the past.
Adobe released new guidance for the rest of this year and 2019. With 20% growth in the cards, this name is a buy.
The DJIA is not accurately reflecting what's going on in the market and will cause you to miss broader weakness that has taken hold.
The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.
The answer is plenty, but you can't trade that.
Let's check some updated charts to see if our strategy is still on track.
As many are aware...I am a believer that in a sea of green, stocks that are red are short trading candidates over the very short term. Conversely, in a sea of red, stocks that are green are long trading candidates over the very near term. Following ...
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
I always say that you should wait until you get an exogenous reason for stocks to come down and then you should pounce.
It is all about perception, and here are strong names to pick up on market weakness.
These stocks offer not only terrific histories of dividend increases, but are also trading at reasonable valuations.
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
Bulls see a $158 price target, but JNJ needs a rally to $135.28 for a breakout.
These funds from the Shark Tank star's O'Shares series focus on small-cap dividend names, internet giants and large-cap dividend U.S. dividend stocks.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer is bullish on Johnson & Johnson shares.
How can this be? Let's take a look at the camps so we can figure it out.
When investors review a drug company, pay close attention to its pharma performance, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending stocks from the floor of the New York Stock Exchange.
My Netflix short was a big winner yesterday, but I am also long Amazon and Google, which were hit with pretty strong collateral damage.
This quarter Netflix is not going to be the star of earnings season.
The major U.S. indices rose on Friday, closing out the week on a two-day winning streak.
We aren't done moving higher even with the president ready to strike at a moment's notice against any of our allies.
Happy Friday the 13th! These are the stories moving the market ahead of today's opening bell.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Thursday's trending stocks from the floor of the New York Stock Exchange